compiled by Raffy Malenab
De La Salle Lipa
DLSL family congratulates the new Registered Nurses (RN) who have passed the Nurse Licensure Examination last June 2009.
To view the list of DLSL graduates who passed the Nurse Licensure Examination, click HERE
De La Salle Health Sciences Institute
DLSHSI ranks 4th during the 2009 NLE
Batch 2009 of the College of Nursing and School of Midwifery’s BS Nursing program posted a passing rate of 97% during the recent Nurse Licensure Examination (NLE), gaining for DLSHSI the recognition of being the fourth top performing school with 100 or more examinees. Administered by the Board of Nursing of the Professional Regulation Commission (PRC), the overall national passing rate of the June 2009 exams is 41.87%
To read more on this story, click HERE
De La Salle Lipa
DLSL family congratulates the new Registered Nurses (RN) who have passed the Nurse Licensure Examination last June 2009.
To view the list of DLSL graduates who passed the Nurse Licensure Examination, click HERE
De La Salle Health Sciences Institute
DLSHSI ranks 4th during the 2009 NLE
Batch 2009 of the College of Nursing and School of Midwifery’s BS Nursing program posted a passing rate of 97% during the recent Nurse Licensure Examination (NLE), gaining for DLSHSI the recognition of being the fourth top performing school with 100 or more examinees. Administered by the Board of Nursing of the Professional Regulation Commission (PRC), the overall national passing rate of the June 2009 exams is 41.87%
To read more on this story, click HERE
DLSHSI inaugurates MDR TB Treatment Center
CaviteƱos with multi-drug resistant TB (MDRTB) do not have to go far for cure now that the De La Salle Health Sciences Institute has opened the first MDRTB Treatment Center in Region IV-A.
naugurated on July 10, the new MDRTB Treatment Center is the fruit of the partnership between the DLSHSI, the Tropical Disease Foundation Inc.(TDF), and the Department of Health (DOH). The center is expected to provide services to TB patients in Region IV A who have developed resistance to at least two of the most powerful, first-line anti-TB drugs—Isoniazid and Rifampicin.
To read more on this story and the latest issue of FOCUS, click HERE
0 comments:
Post a Comment